HOME › DRUGS › ERLOTINIB
ACTIVE SUBSTANCE / INN

ERLOTINIB

Brand name(s): Erlotinib Accord, Tarceva
EMA LISTED
APPLICATION WITHDRAWN
AUTHORISED
Carcinoma, Non-Small-Cell Lung;Pancreatic Neoplasms
ACTIVE SUBSTANCE
Erlotinib
REGULATORS
EMA
SPONSORS / MAH
Cheplapharm Registration GmbH, Accord Healthcare S.L.U.
TOTAL APPLICATIONS
2
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
TarcevaCheplapharm Registration GmbHAuthorised19/09/2005Carcinoma, Non-Small-Cell Lung;Pancreatic Neoplasms
Erlotinib AccordAccord Healthcare S.L.U.Application withdrawnCarcinoma, Non-Small-Cell Lung;Pancreatic Neoplasms

FULL INTELLIGENCE ON ERLOTINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →